Mumbai Healthtech Startup Skitii Raises Funding to Advance AI Driven Cancer Care

The platform integrates AI-driven emotion recognition, biometric sensors, and generative AI to deliver personalized therapy without requiring active patient engagement.

Mindful Gurukul, the DPIIT-recognized healthtech startup behind Skitii, has raised ₹4 crore in funding from a US-based angel investor at a 150 percent increase in valuation, as it moves to advance clinical trials and regulatory approvals for its AI-powered music therapy platform for cancer care.

The funding is aimed at accelerating validation and regulatory submissions for Skitii, an emotion-adaptive music therapy system designed to autonomously generate and adapt therapeutic music in real time based on the emotional and physiological states of cancer patients.

The platform integrates AI-driven emotion recognition, biometric sensors, and generative AI to deliver personalized music therapy without requiring active patient engagement.

According to the company, the valuation increase reflects investor confidence in Skitii’s technology and its potential application in non-pharmacological cancer care. The platform is positioned to support patients by continuously monitoring emotional states and stress patterns through biometric inputs and responding with tailored therapeutic music.

Commenting on the funding, Dr. Chirag Jain, CEO and Co-founder of Mindful Gurukul, said, “We're seeing exceptional interest from investors who understand the convergence of AI and digital therapeutics. The 100% valuation increase reflects both the innovation of our technology and the scalability of our approach. We're pioneering a fundamentally new category: an AI system that detects what patients feel, understands their physiological stress through biometric sensors, and generates personalized music therapy that evolves with them in real-time.”

Dr. Jain added, “As a doctor with 18 years of clinical experience, I've witnessed how cancer treatment focuses almost exclusively on destroying tumors while largely ignoring the suffering patients endure during the process. We're building technology that addresses this gap-a living, adaptive intervention that's available 24/7, responding to patients when they need it most. This funding enables us to validate our approach through rigorous clinical trials and bring this innovation to patients globally.”

The company has filed patents covering the integration of emotion recognition, biometric monitoring, and is preparing to collaborate with hospitals for clinical validation across cancer patient populations.

Stay tuned for more such updates on Digital Health News